Quarterly report · Q3
9627.TEDINET S100QELB
Period2022-05-01 → 2023-01-31
Filed2023-03-17
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥263.9bn | 2022-05-01 → 2023-01-31 | Cons. | Net sales |
| Revenue | ¥316.2bn | 2021-05-01 → 2022-04-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥234.6bn | 2021-05-01 → 2022-01-31 | Cons. | Net sales |
| Operating income | ¥11.7bn | 2022-05-01 → 2023-01-31 | Cons. | Operating income |
| Operating income | ¥10.2bn | 2021-05-01 → 2022-01-31 | Cons. | Operating income |
| Ordinary income | ¥12.4bn | 2022-05-01 → 2023-01-31 | Cons. | Ordinary income |
| Ordinary income | ¥16.0bn | 2021-05-01 → 2022-04-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥10.8bn | 2021-05-01 → 2022-01-31 | Cons. | Ordinary income |
| Profit before tax | ¥12.1bn | 2022-05-01 → 2023-01-31 | Cons. | Income before income taxes |
| Profit before tax | ¥10.7bn | 2021-05-01 → 2022-01-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥6.6bn | 2022-05-01 → 2023-01-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥7.1bn | 2021-05-01 → 2022-04-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥6.2bn | 2021-05-01 → 2022-01-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥6.6bn | 2022-05-01 → 2023-01-31 | Cons. | Profit loss |
| Net income | ¥6.2bn | 2021-05-01 → 2022-01-31 | Cons. | Profit loss |
| Total assets | ¥229.6bn | at 2023-01-31 | Cons. | Assets |
| Total assets | ¥212.5bn | at 2022-04-30 | Cons. | Assets |
| Total assets | ¥208.0bn | at 2022-01-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥105.8bn | at 2023-01-31 | Cons. | Liabilities |
| Total liabilities | ¥93.5bn | at 2022-04-30 | Cons. | Liabilities |
| Net assets / equity | ¥123.7bn | at 2023-01-31 | Cons. | Net assets |
| Net assets / equity | ¥119.0bn | at 2022-04-30 | Cons. | Net assets |
| Net assets / equity | ¥118.1bn | at 2022-01-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥46.2bn | at 2023-01-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥59.7bn | at 2022-04-30 | Cons. | Cash and deposits |
| EPS (basic) | ¥188.7 | 2022-05-01 → 2023-01-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥80.4 | 2022-11-01 → 2023-01-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥201.47 | 2021-05-01 → 2022-04-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥176.89 | 2021-05-01 → 2022-01-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥82.27 | 2021-11-01 → 2022-01-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 53.9% | at 2023-01-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 56.0% | at 2022-04-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 56.8% | at 2022-01-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 34
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2022-05-01 → 2023-01-31 | ¥8.7bn |
| Otherother segments | revenue external | 2022-05-01 → 2023-01-31 | ¥8.7bn |
| Otherother segments | revenue intersegment | 2022-05-01 → 2023-01-31 | ¥43m |
| Otherother segments | segment ordinary income | 2022-05-01 → 2023-01-31 | −¥2m |
| Reconciling Itemsreconciling | revenue | 2022-05-01 → 2023-01-31 | −¥43m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-05-01 → 2023-01-31 | −¥43m |
| Reconciling Itemsreconciling | segment ordinary income | 2022-05-01 → 2023-01-31 | −¥6.4bn |
| jpcrp040300-q3r_E04896-000Dispensing Pharmacyreportable segment | revenue | 2022-05-01 → 2023-01-31 | ¥236.4bn |
| jpcrp040300-q3r_E04896-000Dispensing Pharmacyreportable segment | revenue external | 2022-05-01 → 2023-01-31 | ¥236.4bn |
| jpcrp040300-q3r_E04896-000Dispensing Pharmacyreportable segment | segment ordinary income | 2022-05-01 → 2023-01-31 | ¥18.0bn |
| jpcrp040300-q3r_E04896-000Drug And Cosmetic Storereportable segment | revenue | 2022-05-01 → 2023-01-31 | ¥18.8bn |
| jpcrp040300-q3r_E04896-000Drug And Cosmetic Storereportable segment | revenue external | 2022-05-01 → 2023-01-31 | ¥18.8bn |
| jpcrp040300-q3r_E04896-000Drug And Cosmetic Storereportable segment | segment ordinary income | 2022-05-01 → 2023-01-31 | ¥737m |
| —segment total | revenue | 2022-05-01 → 2023-01-31 | ¥263.9bn |
| —segment total | revenue external | 2022-05-01 → 2023-01-31 | ¥263.9bn |
| —segment total | revenue intersegment | 2022-05-01 → 2023-01-31 | ¥43m |
| —segment total | segment ordinary income | 2022-05-01 → 2023-01-31 | ¥18.8bn |
| Otherother segments | revenue | 2021-05-01 → 2022-01-31 | ¥9.6bn |
| Otherother segments | revenue external | 2021-05-01 → 2022-01-31 | ¥9.5bn |
| Otherother segments | revenue intersegment | 2021-05-01 → 2022-01-31 | ¥71m |
| Otherother segments | segment ordinary income | 2021-05-01 → 2022-01-31 | −¥108m |
| Reconciling Itemsreconciling | revenue | 2021-05-01 → 2022-01-31 | −¥71m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-05-01 → 2022-01-31 | −¥71m |
| Reconciling Itemsreconciling | segment ordinary income | 2021-05-01 → 2022-01-31 | −¥5.4bn |
| jpcrp040300-q3r_E04896-000Dispensing Pharmacyreportable segment | revenue | 2021-05-01 → 2022-01-31 | ¥209.8bn |
| jpcrp040300-q3r_E04896-000Dispensing Pharmacyreportable segment | revenue external | 2021-05-01 → 2022-01-31 | ¥209.8bn |
| jpcrp040300-q3r_E04896-000Dispensing Pharmacyreportable segment | segment ordinary income | 2021-05-01 → 2022-01-31 | ¥17.8bn |
| jpcrp040300-q3r_E04896-000Drug And Cosmetic Storereportable segment | revenue | 2021-05-01 → 2022-01-31 | ¥15.3bn |
| jpcrp040300-q3r_E04896-000Drug And Cosmetic Storereportable segment | revenue external | 2021-05-01 → 2022-01-31 | ¥15.3bn |
| jpcrp040300-q3r_E04896-000Drug And Cosmetic Storereportable segment | segment ordinary income | 2021-05-01 → 2022-01-31 | −¥1.5bn |
| —segment total | revenue | 2021-05-01 → 2022-01-31 | ¥234.7bn |
| —segment total | revenue external | 2021-05-01 → 2022-01-31 | ¥234.6bn |
| —segment total | revenue intersegment | 2021-05-01 → 2022-01-31 | ¥71m |
| —segment total | segment ordinary income | 2021-05-01 → 2022-01-31 | ¥16.2bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 380
| Item | Context | Value | Unit |
|---|---|---|---|
| Net sales | Prior1YTDDuration_jpcrp040300-q3r_E04896-000DispensingPharmacyReportableSegmentsMember | 209793000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q3r_E04896-000DrugAndCosmeticStoreReportableSegmentsMember | 15286000000 | JPY |
| Net sales | Prior1YTDDuration_OtherReportableSegmentsMember | 9601000000 | JPY |
| Net sales | Prior1YTDDuration_ReportableSegmentsMember | 234681000000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -71000000 | JPY |
| Net sales | Prior1YTDDuration | 234610000000 | JPY |
| Ordinary income | Prior1YTDDuration_jpcrp040300-q3r_E04896-000DispensingPharmacyReportableSegmentsMember | 17784000000 | JPY |
| Ordinary income | Prior1YTDDuration_jpcrp040300-q3r_E04896-000DrugAndCosmeticStoreReportableSegmentsMember | -1474000000 | JPY |
| Ordinary income | Prior1YTDDuration_OtherReportableSegmentsMember | -108000000 | JPY |
| Ordinary income | Prior1YTDDuration_ReportableSegmentsMember | 16202000000 | JPY |
| Ordinary income | Prior1YTDDuration_ReconcilingItemsMember | -5401000000 | JPY |
| Ordinary income | Prior1YTDDuration | 10800000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E04896-000DispensingPharmacyReportableSegmentsMember | 236396000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E04896-000DrugAndCosmeticStoreReportableSegmentsMember | 18836000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_OtherReportableSegmentsMember | 8672000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReportableSegmentsMember | 263906000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 263906000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E04896-000DispensingPharmacyReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E04896-000DrugAndCosmeticStoreReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_OtherReportableSegmentsMember | 43000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReportableSegmentsMember | 43000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -43000000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E04896-000DispensingPharmacyReportableSegmentsMember | 236396000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E04896-000DrugAndCosmeticStoreReportableSegmentsMember | 18836000000 | JPY |
| Net sales | CurrentYTDDuration_OtherReportableSegmentsMember | 8716000000 | JPY |
| Net sales | CurrentYTDDuration_ReportableSegmentsMember | 263949000000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -43000000 | JPY |
| Net sales | CurrentYTDDuration | 263906000000 | JPY |
| Ordinary income | CurrentYTDDuration_jpcrp040300-q3r_E04896-000DispensingPharmacyReportableSegmentsMember | 18023000000 | JPY |
| Ordinary income | CurrentYTDDuration_jpcrp040300-q3r_E04896-000DrugAndCosmeticStoreReportableSegmentsMember | 737000000 | JPY |
| Ordinary income | CurrentYTDDuration_OtherReportableSegmentsMember | -2000000 | JPY |
| Ordinary income | CurrentYTDDuration_ReportableSegmentsMember | 18758000000 | JPY |
| Ordinary income | CurrentYTDDuration_ReconcilingItemsMember | -6390000000 | JPY |
| Ordinary income | CurrentYTDDuration | 12367000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2023-03-17 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第54期第３四半期（自 2022年11月１日 至 2023年１月31日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社アインホールディングス | |
| Company name in english cover page | FilingDateInstant | AIN HOLDINGS INC. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 大谷 喜一 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)札幌市白石区東札幌５条２丁目４番30号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)011（814）1000（代表） | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)代表取締役専務 水島 利英 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)札幌市白石区東札幌５条２丁目４番30号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)011（814）1000（代表） | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)代表取締役専務 水島 利英 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |